首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Biomarkers in neuropsychiatry

缩写:

ISSN:2666-1446

e-ISSN:

IF/分区:0.0/

文章目录 更多期刊信息

共收录本刊相关文章索引23
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Ming-Ray Xu,Trey W McGonigle,Jinyuan Liu et al. Ming-Ray Xu et al.
Objective: We examined the effect of delirium and catatonia on psychosis symptom presentation in trauma intensive care unit (TICU) patients without previous history of serious psychiatric illness. ...
Diane C Gooding,Fabu P Carter,Emre Umucu et al. Diane C Gooding et al.
Background: Despite the disproportionate impact of Alzheimer's disease (AD) dementia on Black/African-American and American Indian/Alaska Native groups, they have been underrepresented in biomarker research. Research inve...
Erik Velez-Perez,Nicolas Raymond,Chelsea Kiely et al. Erik Velez-Perez et al.
Background: Electroretinographic dysfunction is observed in psychosis, with a-wave and b-wave amplitudes potentially serving as biomarkers. Insulin resistance (IR) and childhood trauma (CT) have also been associated with ...
Tapas K Sur,Tanmoy Mondal,Zarish Noreen et al. Tapas K Sur et al.
Alzheimer's disease (AD) is a heterogeneous neurodegenerative disease, with no standard biomarker(s) to detect or confirm its risk at an early stage. The prevalence of AD increases exponentially worldwide in people of ages over 65 and older...
Brett A Clementz,Ishanu Chattopadhyay,S Kristian Hill et al. Brett A Clementz et al.
Objective: The B-SNIP consortium validated neurobiologically defined psychosis Biotypes (BT1, BT2, BT3) using cognitive and psychophysiological measures. B-SNIP's biomarker panel is not practical for most settings. Previo...
Walid Yassin,Kendra M Loedige,Cassandra M J Wannan et al. Walid Yassin et al.
The past decade witnessed substantial discoveries related to the psychosis spectrum. Many of these discoveries resulted from pursuits of objective and quantifiable biomarkers in tandem with the application of analytical tools such as machin...
Jonatan M Panula,Athanasios Gotsopoulos,Jussi Alho et al. Jonatan M Panula et al.
As many as one third of the patients diagnosed with schizophrenia do not respond to first-line antipsychotic medication. This group may benefit from the atypical antipsychotic medication clozapine, but initiation of treatment is often delay...
Rui Liu,Ernest V Pedapati,Lauren M Schmitt et al. Rui Liu et al.
Objective: Fragile X Syndrome (FXS) is the leading monogenic cause of intellectual disability and autism spectrum disorder. Currently, there are no established biomarkers for predicting and monitoring drug effects in FXS,...
Francesco Luciano Donati,Armando D&#x;Agostino,Fabio Ferrarelli Francesco Luciano Donati
Schizophrenia (SCZ) is a severe psychotic disorder that affects up to 1% of the US population and it is associated with progressive impairment in social functioning and cognition. Nonetheless, despite its high burden, the pathophysiology of...
Danny Perez Sierra,Ashutosh Tripathi,Anilkumar Pillai Danny Perez Sierra
Complement system is one of the most important defense mechanisms of the innate immune system. In addition to their roles in immune regulation, complement proteins are also involved in neurodevelopment and adult brain plasticity. Complement...